BGLC — Bionexus Gene Lab Balance Sheet
0.000.00%
Last trade - 00:00- $9.22m
- $8.40m
- $9.51m
- 43
- 60
- 36
- 43
Annual balance sheet for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.7 | 0.579 | 0.612 | 2.62 | 1.58 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.02 | 3.44 | 2.93 | 0.98 | 1.66 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7.99 | 7.15 | 6.02 | 8.05 | 7.43 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.85 | 1.68 | 1.57 | 1.65 | 1.74 |
| Long Term Investments | |||||
| Total Assets | 10.1 | 9.57 | 8.74 | 11.4 | 10.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.37 | 2.33 | 2 | 1.63 | 1.95 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.45 | 2.39 | 2.08 | 1.74 | 2.11 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 6.66 | 7.18 | 6.67 | 9.66 | 8.32 |
| Total Liabilities & Shareholders' Equity | 10.1 | 9.57 | 8.74 | 11.4 | 10.4 |
| Total Common Shares Outstanding |